Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Silence Therapeutics plc       GB0008433350

SILENCE THERAPEUTICS PLC

  Report  
SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Silence Therapeutics : Results of Placing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 12:28pm EDT

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

For immediate release

Patisserie Holdings PLC

12 October 2018

Results of Placing to raise approximately £15.7m

Further to the earlier announcement in relation to the proposed placing of ordinary shares, the Company announces that 31,451,100 ordinary shares (the 'Placing Shares') have been placed with institutional investors and were placed at a price of 50p per share via an accelerated bookbuild (the 'Placing'). Canaccord Genuity ('Canaccord Genuity')acted as nominated adviser, sole bookrunner and broker in connection with the Placing.The Placing raised approximately £15.7 million before expenses. Application will be made for the admission of 31,451,100 ordinary shares to trading on AIM. It is expected that admission of (a) the Firm Placing Shares comprising 10,000,000 ordinary shares will become effective at 8.00 a.m. on 18 October 2018 and that dealings in the Firm Placing Shares will commence at that time and (b) the Conditional Placing Shares comprising 21,451,100 ordinary shares will become effective at 8.00 a.m. on the Business Day following the General Meeting of the Company (expected to on or around 1 November 2018) and that dealings in the Firm Placing Shares will commence at that time and the Placing Shares shall rank pari passuwith the existing issued ordinary shares of the Company.

Following completion of the Placing the Company will have 135,322,452 Ordinary Shares in issue.

Enquiries

Patisserie Holdings PLC +44 (0)121 777 7000

Luke Johnson, Executive Chairman

Paul May, Chief Executive Officer

Nomad and Broker

Canaccord Genuity Limited +44 (0)20 7523 8000

Chris Connors

Henry Fitzgerald-O'Connor

Financial Public Relations

Maitland +44 (0) 20 7379 5151

Sam Cartwright

Jonathan Cook

Disclaimer

Silence Therapeutics plc published this content on 12 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 October 2018 16:27:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SILENCE THERAPEUTICS PLC
04/30SILENCE THERAPEUTICS : Additional Listing
PU
04/25SILENCE THERAPEUTICS : Announces Board Changes
PU
04/18SILENCE THERAPEUTICS : Appointment of Chief Financial Officer
PU
04/18SILENCE THERAPEUTICS : Publication of Annual Report
PU
04/16SILENCE THERAPEUTICS : Announces Board Change
PU
04/16SILENCE THERAPEUTICS : appoints Head of R&D and CMO
PU
03/29SILENCE THERAPEUTICS : submits clinical trial application to MHRA
AQ
03/27SILENCE THERAPEUTICS : submits CTA for SLN124
PU
01/16SILENCE THERAPEUTICS : SLN124 granted Orphan Drug Designation by EMA for the tre..
AQ
01/15SILENCE THERAPEUTICS : SLN124 granted Orphan Drug Designation by EMA
PU
More news
Financials (GBP)
Sales 2019 20,8 M
EBIT 2019 -
Net income 2019 -
Debt 2019 32,8 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 3,63x
EV / Sales 2020 1,78x
Capitalization 42,7 M
Chart SILENCE THERAPEUTICS PLC
Duration : Period :
Silence Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
David Horn Solomon Chief Executive Officer & Director
Andrew John McGlashan Richards Non-Executive Chairman
Rob Quinn Chief Financial Officer
Marie W. Lindholm Head-Technology Innovation
Stephen B. Parker Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SILENCE THERAPEUTICS PLC55
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
CELLTRION, INC.--.--%19 604
INCYTE CORPORATION28.56%17 530
EXACT SCIENCES CORPORATION53.53%12 511